Astellas Pharma is a Japanese multinational pharmaceutical company specializing in oncology, urology, and transplant rejection drugs. Founded in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, Astellas focuses on new treatments for cancer and rare diseases.
Astellas operates through research-driven drug discovery, clinical development, and commercialization. The company invests heavily in R&D, partnering with academic institutions and biotech firms to develop novel therapies. Astellas' pipeline includes small molecules, biologics, and cell therapies.
| Drug Name | Therapeutic Area | Approval Year |
|---|---|---|
| Xtandi | Prostate Cancer | 2012 |
| Evrenzo | Schizophrenia | 2015 |
| Padcev | Bladder Cancer | 2019 |
Astellas operates in over 70 countries, with headquarters in Tokyo. The company's drugs treat conditions like metastatic prostate cancer (Xtandi), schizophrenia (Evrenzo), and advanced bladder cancer (Padcev). Astellas aims to improve patient outcomes through precision medicine and targeted therapies.
Some assume Astellas only focuses on oncology, but it also develops treatments for rare diseases and infectious diseases. Unlike pure biotech firms, Astellas maintains a balanced portfolio of in-house and partnered drugs. The company's origins trace to two separate Japanese firms, not a single entity.
In 2023, Astellas acquired Audentes Therapeutics for $3 billion, expanding its gene therapy capabilities. This deal underscores Astellas' commitment to modern treatments beyond traditional small-molecule drugs.
Astellas Pharma remains a key player in global healthcare, driven by innovation and strategic partnerships. Its focus on oncology and rare diseases positions it as a leader in precision medicine.